HONG KONG, Sept. 26, 2014 /PRNewswire/ —China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 2014 annual general meeting of shareholders at its Hong Kong office at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 11, 2014 (8:00 a.m. U.S. Eastern Time on December 11, 2014).
Shareholders of record as of October 31, 2014 will be entitled to receive notice of and vote at the annual general meeting. China Cord Blood Corporation filed its annual report on Form 20-F, including its audited financial statements for the fiscal year ended March 31, 2014, with the U.S. Securities and Exchange Commission (the "SEC") on July 31, 2014. CCBC’s annual report on Form 20-F can be accessed at the Investor Center section of the Company’s website at http://www.chinacordbloodcorp.com, as well as on the SEC’s website at http://www.sec.gov. Shareholders may request a meeting notice, proxy statement and hard copy of the annual report on Form 20-F free of charge by contacting email@example.com.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Mr. Bill Zima
Tel: (+86) 10-6583-7511 (China) or 646-405-5185 (U.S.)